Clarity Pharmaceuticals Ltd (CU6)

Currency in AUD
3.660
+0.040(+1.10%)
Closed·
CU6 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CU6 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.5903.705
52 wk Range
1.4308.975
Key Statistics
Bid/Ask
3.66 / 3.72
Prev. Close
3.62
Open
3.62
Day's Range
3.59-3.705
52 wk Range
1.43-8.975
Volume
1.74M
Average Volume (3m)
3.36M
1-Year Change
-41.9%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CU6 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.480
Upside
+104.37%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

Clarity Pharmaceuticals Ltd Company Profile

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company’s products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. It develops theranostic therapy and imaging products for the treatment of cancer in children and adults. The company was incorporated in 2010 and is based in Sydney, Australia.

Compare CU6 to Peers and Sector

Metrics to compare
CU6
Peers
Sector
Relationship
P/E Ratio
−28.0x−1.7x−0.5x
PEG Ratio
0.75−0.020.00
Price/Book
10.7x6.2x2.6x
Price / LTM Sales
126.3x8.5x3.3x
Upside (Analyst Target)
132.2%245.5%40.3%
Fair Value Upside
Unlock0.0%5.1%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.480
(+104.37% Upside)

Earnings

Latest Release
Feb 28, 2025
EPS / Forecast
-0.07 / -5.50
Revenue / Forecast
4.69M / 8.00M
EPS Revisions
Last 90 days

CU6 Income Statement

People Also Watch

4.090
DRO
-3.31%
1.510
DYL
+2.03%
0.935
GEM
+1.63%
217.410
MQG
+0.36%

FAQ

What Stock Exchange Does Clarity Pharmaceuticals Trade On?

Clarity Pharmaceuticals is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Clarity Pharmaceuticals?

The stock symbol for Clarity Pharmaceuticals is "CU6."

What Is the Clarity Pharmaceuticals Market Cap?

As of today, Clarity Pharmaceuticals market cap is 1.36B.

What Is Clarity Pharmaceuticals's Earnings Per Share (TTM)?

The Clarity Pharmaceuticals EPS (TTM) is -0.16.

From a Technical Analysis Perspective, Is CU6 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Clarity Pharmaceuticals Stock Split?

Clarity Pharmaceuticals has split 0 times.

How Many Employees Does Clarity Pharmaceuticals Have?

Clarity Pharmaceuticals has 50 employees.

What is the current trading status of Clarity Pharmaceuticals (CU6)?

As of 16 Aug 2025, Clarity Pharmaceuticals (CU6) is trading at a price of 3.66, with a previous close of 3.62. The stock has fluctuated within a day range of 3.59 to 3.71, while its 52-week range spans from 1.43 to 8.98.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.